Skip to content

Efficacy of Fu's Subcutaneous Needling for Trigeminal Neuralgia :A prospective, self-controlled trial

Efficacy of Fu's subcutaneous needling for Trigeminal Neuralgia :A prospective, self-controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2200005655
Enrollment
Unknown
Registered
2022-02-23
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigeminal Neuralgia

Interventions

:Fu's subcutaneous needling

Sponsors

Yangzhou Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: A. At least three attacks of unilateral facial pain fulfilling criteria B and C B. Occurring in one or more divisions of the trigeminal nerve, with no radiation beyond the trigeminal distribution C. Pain has at least three of the following four characteristics: a. recurring in paroxysmal attacks lasting from a fraction of a second to 2 minutes b. severe intensity c. electric shock-like, shooting, stabbing or sharp in quality d. precipitated by innocuous stimuli to the affected side of the face D. No clinically evident neurological deficit E. Not better accounted for by another ICHD-3 diagnosisuced ; F. Duration ranges from 2 weeks to 6 months at time of recruitment; G. Age ranges from 18 to 80; H. Signed informed consent.

Exclusion criteria

Exclusion criteria: Patients with STN, such as tumors in the cerebellopontine horn region, trigeminal neurilemmoma, multiple sclerosis, and other neuralgia patients confused with TN, such as odontogenic pain, herpes zoster, migraine or plexiform neuralgia; combination of heart, liver, or kidney failure endanger the safety of life at any time; younger than 18 years or older than 80 years; those who do not receive acupuncture therapy; women with pregnancy and lactation; participate in other studies; aphasia, and severe cognitive deficits.

Design outcomes

Primary

MeasureTime frame
Numerical Rating Scale;medicine dosage;

Secondary

MeasureTime frame
Barrow Neurology Institute Pain Scale scores;Patient Global Impression of Change scores;Brief Pain Inventory–Facial scores;the Constant Face Pain Questionnaire scores;

Contacts

Public ContactGao Youling

Yangzhou Hospital of Traditional Chinese Medicine

409183383@qq.com15150808462

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026